 Mercaptopurine is a drug used in the treatment of acute lymphoblastic leukemia. It has a low bioavailability due to its poor solubility, which can be improved by using a carrier such as polydopamine-modified mesoprosilica with adsorb zinc ions. These carriers are spherical, have a diameter of approximately 200 nanometers, and do not agglomerate. They also have a Zeta potential value indicating they are not prone to aggregation. Furthermore, the drug is released slowly over a long period of time, making it suitable for intravenous administration. The drug is released from the carrier for 15 hours, and no burst release was observed. Additionally, the carrier also releases small amounts of zinc, which are important in the treatment of the disease because they can prevent some of the adverse effects of chemotherapy. Overall, the results are promising and have great application potential. This article was authored by Mariusz Sandmuski, Martina Kochanaka, Maria DeLugas, and others.